Stephen Gordon Sells 20,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDXGet Free Report) CFO Stephen Gordon sold 20,000 shares of the business’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $141.40, for a total value of $2,828,000.00. Following the sale, the chief financial officer now directly owns 21,299 shares of the company’s stock, valued at $3,011,678.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Stephen Gordon also recently made the following trade(s):

  • On Monday, May 6th, Stephen Gordon sold 15,000 shares of TransMedics Group stock. The shares were sold at an average price of $128.00, for a total transaction of $1,920,000.00.
  • On Monday, April 1st, Stephen Gordon sold 15,000 shares of TransMedics Group stock. The shares were sold at an average price of $74.01, for a total value of $1,110,150.00.
  • On Friday, March 8th, Stephen Gordon sold 1,903 shares of TransMedics Group stock. The stock was sold at an average price of $87.63, for a total value of $166,759.89.
  • On Monday, March 4th, Stephen Gordon sold 15,000 shares of TransMedics Group stock. The shares were sold at an average price of $82.80, for a total value of $1,242,000.00.

TransMedics Group Stock Performance

TMDX opened at $136.40 on Friday. The company has a market capitalization of $4.49 billion, a price-to-earnings ratio of -401.18 and a beta of 1.87. The business’s 50-day moving average price is $107.57 and its two-hundred day moving average price is $89.59. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $144.23. The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76.

TransMedics Group (NASDAQ:TMDXGet Free Report) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The firm had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. During the same period in the previous year, the business earned ($0.08) EPS. The company’s revenue was up 132.9% compared to the same quarter last year. Equities analysts expect that TransMedics Group, Inc. will post 0.76 EPS for the current fiscal year.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of TransMedics Group by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company’s stock worth $99,341,000 after purchasing an additional 29,798 shares during the last quarter. Moody Aldrich Partners LLC grew its position in shares of TransMedics Group by 110.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 46,312 shares of the company’s stock valued at $3,655,000 after acquiring an additional 24,290 shares during the period. American Century Companies Inc. increased its stake in shares of TransMedics Group by 271.2% during the 3rd quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock worth $26,661,000 after purchasing an additional 355,755 shares during the last quarter. Qube Research & Technologies Ltd raised its holdings in shares of TransMedics Group by 31.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company’s stock valued at $4,624,000 after purchasing an additional 20,081 shares during the period. Finally, Sei Investments Co. lifted its stake in TransMedics Group by 17.8% in the 3rd quarter. Sei Investments Co. now owns 386,082 shares of the company’s stock valued at $21,139,000 after purchasing an additional 58,269 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Morgan Stanley upped their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. Piper Sandler reiterated an “overweight” rating and issued a $120.00 target price (up from $95.00) on shares of TransMedics Group in a report on Wednesday, May 1st. TD Cowen boosted their price target on shares of TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Oppenheimer raised their price objective on TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. Finally, Canaccord Genuity Group boosted their target price on TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $119.00.

Read Our Latest Research Report on TMDX

TransMedics Group Company Profile

(Get Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Articles

Insider Buying and Selling by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.